Replies to post #76657 on Anavex Life Sciences Corp (AVXL)

[bas2020]

I'd like to know if any of Anavex's scientists are collaborating with Biogen on these tests. It would help the relationship and further the understanding of 2-73's MoA and its scope.

MS is a safe area for Biogen to begin its testing, since Anavex is not focusing its efforts there, while at the same time not discrediting abucanumab's progress on Alz (at least not initially).

I wonder if Biogen might be secretly evaluating 2-73 for other indications (i.e. Alz) in its other labs.

So many questions...